426829-61-0

Basic information

• Product Name: N-Benzyl-6-chloro-2-pyrazinamine
• Synonyms: N-Benzyl-6-chloro-2-pyrazinamine;2-(benzylamino)-6-chloropyrazine
• CAS NO: 426829-61-0
• Molecular Formula: C₁₁H₁₀ClN₃
• Molecular Weight: 220
• Mol File: 426829-61-0.mol

Chemical Properties

• Boiling Point: 359.5±37.0 °C(Predicted)
• Appearance: /
• Density: 1.307±0.06 g/cm3(Predicted)
• Storage Temp.: under inert gas (nitrogen or Argon) at 2–8 °C
• PKA: 0.89±0.10(Predicted)
• CAS DataBase Reference: N-Benzyl-6-chloro-2-pyrazinamine(CAS DataBase Reference)
• NIST Chemistry Reference: N-Benzyl-6-chloro-2-pyrazinamine(426829-61-0)
• EPA Substance Registry System: N-Benzyl-6-chloro-2-pyrazinamine(426829-61-0)

Safety Data

• HazardClass: IRRITANT
• Hazardous Substances Data: 426829-61-0(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
N-Benzyl-6-chloro-2-pyrazinamine is used as a key intermediate in the synthesis of potential drug candidates for its antimicrobial properties, making it a promising candidate for the development of new antibiotics or antifungal agents.
Used in Agrochemical Industry:
N-Benzyl-6-chloro-2-pyrazinamine is used as a chemical building block in the development of agrochemicals, where its antimicrobial properties can be harnessed to protect crops from various diseases and pests.
Used in Organic Chemistry Research:
N-Benzyl-6-chloro-2-pyrazinamine is used as a versatile and reactive compound in organic chemistry research, where its unique structure and functional groups can be explored for the synthesis of new organic compounds and the study of chemical reactions.
Used in Medicinal Chemistry:
N-Benzyl-6-chloro-2-pyrazinamine is used as a valuable tool in medicinal chemistry for the design and synthesis of new therapeutic compounds, leveraging its antimicrobial properties and reactivity to combat various infectious diseases.

Upstream product

• 4774-14-5 2,6-dichloropyrazine 
• 100-46-9 benzylamine 

Relevant articles and documents

DIHYDROQUINOLINE-2-ONE DERIVATIVES

The invention provides novel compounds having the general formula (I) wherein R1, R2, R3, R4, R5, R6, R7, A1, A2 and A3 are as described herein, compositions including the compounds and methods of using the compounds. These compounds are useful for therapy or prophylaxis in a mammal, and in particular as aldosterone synthase (CYP11B2 or CYP11B1) inhibitors for the treatment or prophylaxis of chronic kidney disease, congestive heart failure, hypertension, primary aldosteronism and Cushing syndrome.

NEW DIHYDROQUINOLINE-2-ONE DERIVATIVES

The invention provides novel compounds having the general formula (I) wherein R1, R2, R3, R4? R5, R6, R7, A1, A2 and A3 are as described herein, compositions including the compounds and methods of using the compounds.

Novel inhibitors of B-RAF based on a disubstituted pyrazine scaffold. Generation of a nanomolar lead

B-RAF, a serine/threonine kinase, plays an important role in the development of certain classes of cancer, especially melanoma. As a result of high-throughput screening of a 23,000 compound library, 2-(3,4,5- trimethoxyphenylamino)-6-(3-acetamidophenyl)pyrazine, 1, was identified as a low micromolar (IC50 = 3.5 μM) B-RAF inhibitor. This compound was chosen as the starting point of a program aimed at producing potent inhibitors of B-RAF. We have synthesized a series of 40 novel compounds, which involved extensive modifications to the 2-(3,4,5-trimethoxyphenylamino) moiety (ring A) of 1. Their biological profiles against isolated B-RAF and mutated B-RAF in a cellular assay have been determined. These efforts led to the identification of two compounds exhibiting activities lower than 800 nM against B-RAF.

KINASE INHIBITORS

A compound of the general formula (I) or pharmaceutically acceptable salts, hydrates, solvates, crystal forms or diastereomers thereof is described. A method of treating protein kinase-associated disease states using the compound of formula (I) is also de

Novel compounds and their use

A compound of the general formula (I): wherein R1, R2, X, Y and Z are as described in the specification.